domingo, 1 de julio de 2018

Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis. - PubMed - NCBI

Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis. - PubMed - NCBI



 2018 Jun;109(6):2027-2035. doi: 10.1111/cas.13595. Epub 2018 May 15.

Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis.

Abstract

BRCA-related breast carcinoma can be prevented through prophylactic surgery and an intensive follow-up regimen. However, BRCA genetictests cannot be routinely performed, and some BRCA mutations could not be defined as deleterious mutations or normal variants. Therefore, an easy functional assay of BRCA will be useful to evaluate BRCA status. As it has been reported that BRCA functions in the regulation of centrosome number, we focused on centrosome number in cancer tissues. Here, 70 breast cancer specimens with known BRCA status were analyzed using immunofluorescence of γ-tubulin (a marker of centrosome) foci. The number of foci per cell was higher in cases with BRCA mutation compared to wild-type cases, that is, 1.9 (95% confidence interval [CI], 1.5-2.3) vs 0.5 (95% CI, 0.2-0.8) (P < .001). Specifically, foci numbers per cell in BRCA1 and BRCA2 mutation cases were 1.2 (95% CI, 0.6-1.8) and 2.2 (95% CI, 1.7-2.6), respectively, both higher than those in wild-type cases (P = .042 and P < .0001, respectively). The predictive value of γ-tubulin foci as determined by area under the curve (AUC = 0.86) for BRCA status was superior to BRCAPRO (AUC = 0.69), Myriad Table (AUC = 0.61), and KOHBRA BRCA risk calculator (AUC = 0.65) pretest values. The use of γ-tubulin foci to predict BRCA status had sensitivity = 83% (19/23), specificity = 89% (42/47), and positive predictive value = 77% (20/26). Thus, γ-tubulin immunofluorescence, a functional assessment of BRCA, can be used as a new prospective test of BRCA status.

KEYWORDS:

BRCA-related breast cancer; BRCA1; BRCA2; centrosome; immunofluorescence

PMID:
 
29601120
 
PMCID:
 
PMC5989840
 
DOI:
 
10.1111/cas.13595

[Indexed for MEDLINE] 
Free PMC Article

No hay comentarios:

Publicar un comentario